Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Thomas J, Reid"'
Autor:
Krishnansu S. Tewari, Michael W. Sill, Michael J. Birrer, Richard T. Penson, Helen Huang, David H. Moore, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas J. Reid, Mario M. Leitao, Helen E. Michael, Bradley J. Monk
Publikováno v:
Scientia
Càncer de coll uterí; Platí; Topotecan Cáncer de cuello uterino; Platino; Topotecan Cervical cancer; Platinum; Topotecan Objective To determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::453747f210231077865659980777190e
https://escholarship.org/uc/item/3s2251wz
https://escholarship.org/uc/item/3s2251wz
Publikováno v:
Ultrasound in Obstetrics & Gynecology. 59:668-676
Objective To apply the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), IOTA Simple Rules Risk assessment (SRR), IOTA Assessment of Different NEoplasias in the adneXa (ADNEX) model, and the Ovarian-Adnexal Reporting and Data System (O-R
Autor:
Elizabeth M. Swisher, Carol Aghajanian, David M. O'Malley, Gini F. Fleming, Scott H. Kaufmann, Douglas A. Levine, Michael J. Birrer, Kathleen N. Moore, Nick M. Spirtos, Mark S. Shahin, Thomas J. Reid, Michael Friedlander, Karina Dahl Steffensen, Aikou Okamoto, Vasudha Sehgal, Peter J. Ansell, Minh H. Dinh, Michael A. Bookman, Robert L. Coleman
Publikováno v:
Swisher, E M, Aghajanian, C, O'Malley, D M, Fleming, G F, Kaufmann, S H, Levine, D A, Birrer, M J, Moore, K N, Spirtos, N M, Shahin, M S, Reid, T J, Friedlander, M, Steffensen, K D, Okamoto, A, Sehgal, V, Ansell, P J, Dinh, M H, Bookman, M A & Coleman, R L 2022, ' Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study ', Gynecologic Oncology, vol. 164, no. 2, pp. 245-253 . https://doi.org/10.1016/j.ygyno.2021.12.003
OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker
Autor:
Alexander I. Spira, Thomas J. Reid, Christina Brzezniak, Saiama N. Waqar, Sukhmani K. Padda, Karen Zeman, Daniel Morgensztern, John C. Morris, Michal G. Rose, Jo Ann Hirth, Jane B. Trepel, Arvinda Padmanabhan, Patrick C. Ma
Publikováno v:
British Journal of Cancer
Background This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 followed by reintroduction of platinum plus etoposide in patients with previously treated small-cell lung cancer (SCLC). Methods Patients were treated
Autor:
Angeles Alvarez Secord, Katherine Fuh, Thomas J. Herzog, Tashanna K.N. Myers, Reshma A. Rangwala, Bobbie J. Rimel, Kathleen N. Moore, Sharyn N. Lewin, Mary M. Mullen, Joyce F. Liu, Randy Anderson, Erika Hamilton, Thomas J. Reid, K.A. Mills
Publikováno v:
Journal of Clinical Oncology. 39:TPS5605-TPS5605
TPS5605 Background: The AXL receptor and its activating ligand, GAS6, are important drivers of metastasis and therapeutic resistance in human cancers. This signaling axis represents an attractive target for therapeutic intervention, but the strong pi
Autor:
Helen Huang, Katherine Y. Look, J. Tate Thigpen, Bradley J. Monk, Wui Jin Koh, William T. Creasman, Ana Oaknin, Robert A. Burger, Thomas J. Reid, Frederick B. Stehman, Steven E Waggoner, Lisa M. Landrum, David H. Moore, Michael J. Birrer, Lois M. Ramondetta, Philip J. DiSaia, Michael W. Sill, Richard T. Penson, Helen Michael, Mark F. Brady, Mario M. Leitao, Krishnansu S. Tewari, Larry J. Copeland
Publikováno v:
Tewari, KS; Sill, MW; Penson, RT; Huang, H; Ramondetta, LM; Landrum, LM; et al.(2017). Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). The Lancet, 390(10103), 1654-1663. doi: 10.1016/S0140-6736(17)31607-0. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/2rq1s1px
© 2017 Elsevier Ltd Background On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analys
Autor:
Krishnansu S. Tewari, Sharon Stockman, Thomas J. Reid, Helen Michael, Ana Oaknin, Richard T. Penson, Mario M. Leitao, Michael Method, Harry J. Long, Lisa M. Landrum, Lois M. Ramondetta, Bradley J. Monk, Helen Q. Huang, Lari Wenzel
Publikováno v:
Penson, RT; Huang, HQ; Wenzel, LB; Monk, BJ; Stockman, S; Long, HJ; et al.(2015). Bevacizumab for advanced cervical cancer: Patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). The Lancet Oncology, 16(3), 301-311. doi: 10.1016/S1470-2045(15)70004-5. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/9mm45442
Penson, Richard T; Huang, Helen Q; Wenzel, Lari B; Monk, Bradley J; Stockman, Sharon; Long, Harry J; et al.(2015). Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). The Lancet Oncology, 16(3), 301-311. doi: 10.1016/s1470-2045(15)70004-5. UC Irvine: Institute for Clinical and Translational Science. Retrieved from: http://www.escholarship.org/uc/item/4xk8d9zs
Penson, Richard T; Huang, Helen Q; Wenzel, Lari B; Monk, Bradley J; Stockman, Sharon; Long, Harry J; et al.(2015). Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). The Lancet Oncology, 16(3), 301-311. doi: 10.1016/s1470-2045(15)70004-5. UC Irvine: Institute for Clinical and Translational Science. Retrieved from: http://www.escholarship.org/uc/item/4xk8d9zs
Summary Background GOG 240 was a practice-changing randomised phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall and progression-free survival, and the proportion of patients ac
Autor:
Bradley J. Monk, Thomas J. Reid, Richard T. Penson, Jubilee Brown, Michael W. Sill, David H. Moore, Lisa M. Landrum, Harry J. Long, Krishnansu S. Tewari, Helen Michael, Andres Poveda, Mario M. Leitao
Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025ebbb0362237da512eb4bc31d9cf10
https://europepmc.org/articles/PMC4896296/
https://europepmc.org/articles/PMC4896296/
Autor:
Christina Brzezniak, Daniel Morgensztern, Alexander I. Spira, Bryan Oronsky, Heather A. Wakelee, Sukhmani K. Padda, Saiama N. Waqar, Thomas J. Reid, Karen Zeman, Michal G. Rose, Ellice Yuen-Ming Wong, Nacer Abrouk, Patrick C. Ma
Publikováno v:
Journal of Clinical Oncology. 36:e20575-e20575
e20575Background: RRx-001 is a first-in-class epi-immunotherapeutic drug that targets tumor-associated macrophages and cancer stem cells to reverse chemotherapy resistance in small cell lung cancer...
Autor:
Jeremy G, Perkins, Andrew P, Cap, Brendan M, Weiss, Thomas J, Reid, Charles D, Bolan, Charles E, Bolan
Publikováno v:
Critical Care Medicine. 36:S325-S339
Background: Hemorrhage in trauma is a significant challenge, accounting for 30% to 40% of all fatalities, second only to central nervous system injury as a cause of death. However, hemorrhagic death is the leading preventable cause of mortality in co